

CARDURA[®]

(Doxazosin Mesylate)

1. NAME OF THE MEDICINAL PRODUCT

CARDURA[®]

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active ingredient: doxazosin

The tablets contain doxazosin mesylate equivalent to 2 mg and 4 mg doxazosin.

3. PHARMACEUTICAL FORM

Tablets

4. CLINICAL PARTICULARS

4.1. THERAPEUTIC INDICATIONS

Hypertension

CARDURA[®] (doxazosin) is indicated for the treatment of hypertension and can be used as the initial agent to control blood pressure in the majority of patients.¹⁴ In patients not adequately controlled on a single antihypertensive agent, CARDURA[®] (doxazosin) may be used in combination with another agent such as a thiazide diuretic, a beta-blocker,¹⁰ a calcium antagonist or an angiotensin-converting enzyme inhibitor.

Benign Prostatic Hyperplasia

CARDURA[®] (doxazosin) is indicated for the treatment of clinical symptoms in benign prostatic hyperplasia (BPH) and for reduced urinary flow associated with BPH. CARDURA[®] (doxazosin) may be used in BPH patients who are either hypertensive or normotensive. While the blood pressure changes in normotensive patients with BPH are clinically insignificant,¹ patients with hypertension and BPH have had both conditions effectively treated with doxazosin monotherapy.⁵⁷

4.2. POSOLOGY AND METHOD OF ADMINISTRATION

CARDURA[®] (doxazosin) may be administered either in the morning or in the evening.²

Hypertension

The full dosage range of CARDURA[®] (doxazosin) is 1 mg to 16 mg daily. It is recommended that therapy be initiated at 1 mg once daily for 1 or 2 weeks to minimize the potential for postural hypotension and/or syncope (see section **4.4 Special warnings and precautions for use**). The dosage may then be increased to 2 mg once daily for additional 1 or 2 weeks. If necessary, the daily dosage should then be increased gradually at similar intervals to 4 mg, 8 mg, and 16 mg, as determined by patient response, to achieve the desired reduction in blood pressure.^{11,27} The usual dose is 2 mg to 4 mg once daily.

Benign Prostatic Hyperplasia

The recommended initial dosage of CARDURA[®] (doxazosin) is 1 mg once daily to minimize the potential for postural hypotension and/or syncope (see section **4.4 Special warnings and precautions for use**). Depending on the individual patient's urodynamics and BPH symptomatology, dosage may then be increased to 2 mg and thereafter to 4 mg and up to the maximum recommended dose of 8 mg. The recommended titration interval is 1 to 2 weeks. The usual recommended dose is 2 to 4 mg once daily.

Use in Elderly

Normal adult dosage is recommended.⁷

Use in Renally Impaired Patients

Since the pharmacokinetics of CARDURA[®] (doxazosin) are unchanged in patients with renal insufficiency, and there is no evidence that CARDURA[®] (doxazosin) aggravates existing renal dysfunction, the usual dosages may be used in these patients.^{54,55,56,61}

Use in Hepatically Impaired Patients

See section **4.4 Special warnings and precautions for use**.

Use in Children

The safety and efficacy of CARDURA[®] (doxazosin) in children have not been established.

4.3. CONTRAINDICATIONS

CARDURA[®] (doxazosin) is contraindicated in patients with a known hypersensitivity to quinazolines, doxazosin, or any of the inert ingredients.

4.4. SPECIAL WARNINGS AND PRECAUTIONS FOR USE*Postural Hypotension/Syncope*

As with all alpha-blockers, a very small percentage of patients have experienced postural hypotension evidenced by dizziness and weakness, or rarely loss of consciousness (syncope), particularly with the commencement of therapy (see section **4.2 Posology and method of administration**). When instituting therapy with any effective alpha-blocker, the patient should be advised how to avoid symptoms resulting from postural hypotension and what measures to take should they develop. The patient should be cautioned to avoid situations where injury could result should dizziness or weakness occur during the initiation of CARDURA[®] (doxazosin) therapy.⁹⁶

Use with Phosphodiesterase Type-5 Inhibitors

Concomitant administration of CARDURA[®] (doxazosin) with a phosphodiesterase type-5 (PDE-5) inhibitor should be used with caution as it may lead to symptomatic hypotension in some patients.¹⁰⁴

Impaired Hepatic Function

As with any drug wholly metabolized by the liver, CARDURA[®] (doxazosin) should be administered with caution to patients with evidence of impaired hepatic function³ (see section **5.2 Pharmacokinetic properties**).

Intraoperative Floppy Iris Syndrome

The intraoperative floppy iris syndrome (IFIS), a variant of small pupil syndrome, has been observed during cataract surgery in some patients on or previously treated with alpha₁-blockers. As IFIS may lead to increased procedural complications during the operation, current or past use of alpha-blockers should be made known to the ophthalmologic surgeon in advance of surgery.^{106, 107}

Priapism

Prolonged erections and priapism have been reported with alpha-1 blockers including doxazosin in post marketing experience. In the event of an erection that persists longer than 4 hours, the patient should seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency could result.¹⁰⁸

4.5. INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION

Use with PDE-5 Inhibitors

(see section **4.4 Special warnings and precautions for use - Use with PDE-5 Inhibitors**).¹⁰⁴

CYP3A4 Inhibitors

In vitro studies suggest that doxazosin is a substrate of CYP 3A4. Caution should be exercised when concomitantly administering doxazosin with a strong CYP 3A4 inhibitor, such as clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole (see section **5.2 Pharmacokinetic properties**).¹⁰⁹

Other

Most (98%) of the plasma doxazosin is protein bound.²³ *In vitro* data in human plasma indicate that CARDURA[®] (doxazosin) has no effect on protein binding of digoxin, warfarin, phenytoin or indomethacin.²⁴ CARDURA[®] (doxazosin) has been administered without any adverse drug interaction in clinical experience with thiazide diuretics, furosemide, beta-blockers, non-steroidal anti-inflammatory drugs, antibiotics, oral hypoglycemic drugs, uricosuric agents, or anticoagulants.^{14,25}

In an open-label, randomized, placebo-controlled trial in 22 healthy male volunteers, the administration of a single 1 mg dose of CARDURA[®] (doxazosin) on Day 1 of a 4-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin, and no statistically significant changes in mean C_{max} and mean half-life of doxazosin. The 10% increase in the mean AUC for CARDURA[®] (doxazosin) with cimetidine is within intersubject variation (27%) of the mean AUC for doxazosin with placebo.⁹⁷

4.6. FERTILITY, PREGNANCY AND LACTATION

Although no teratogenic effects were seen in animal testing with CARDURA[®] (doxazosin),²² reduced fetal survival was observed in animals at extremely high doses. These doses were approximately 300 times the maximum human recommended dose.

A single case report demonstrated transfer of doxazosin into human breast milk and animal studies have shown that CARDURA[®] (doxazosin) accumulates in breast milk. (see section 5.3 Preclinical safety data)^{60,110}

As there are no adequate and well controlled studies in pregnant or nursing women, the safety of CARDURA[®] (doxazosin) during pregnancy or lactation has not yet been established. Accordingly, during pregnancy or lactation, CARDURA[®] (doxazosin) should be used only when, in the opinion of the physician, the potential benefit outweighs the potential risk.

4.7. EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

The ability to engage in activities such as operating machinery or operating a motor vehicle may be impaired, especially when initiating CARDURA[®] (doxazosin) therapy.

4.8. UNDESIRABLE EFFECTS

Hypertension

In controlled clinical trials, the most common reactions associated with CARDURA[®] (doxazosin) were of a postural type (rarely associated with syncope) or non-specific and included:

Ear and Labyrinth Disorders: vertigo^{14,26}

Gastrointestinal Disorders: nausea⁵³

General Disorders and Administration Site Conditions: asthenia^{14,26}, edema^{14,26}, fatigue^{14,26}, malaise^{14,26}

Nervous System Disorders: dizziness^{14,26}, headache^{14,26}, postural dizziness^{14,26}, somnolence⁵³, syncope²⁶

Respiratory, Thoracic and Mediastinal Disorders: rhinitis⁵³

Benign Prostatic Hyperplasia

Experience in controlled clinical trials in BPH indicates a similar adverse event profile to that seen in hypertension.

In post-marketing experience, the following additional adverse events have been reported:

Blood and Lymphatic Disorders: leukopenia⁵⁸, thrombocytopenia⁵⁸

Ear and Labyrinth Disorders: tinnitus⁹⁰

Eye Disorders: blurred vision³⁷, IFIS (Intraoperative Floppy Iris Syndrome) (see section 4.4. Special warnings and precautions for use).^{106,107}

Gastrointestinal Disorders: abdominal pain²⁸, constipation⁷⁴, diarrhea²⁸, dyspepsia⁷⁵, flatulence⁷⁶, mouth dry⁶⁴, vomiting²⁸

General Disorders and Administrations Site Conditions: pain⁶⁷

Hepatobiliary Disorders: cholestasis⁵⁹, hepatitis⁵⁹, jaundice³⁵

Immune System Disorders: allergic reaction⁶⁵

Investigations: abnormal liver function tests⁵⁹, weight increase⁶⁸

Metabolism and Nutrition: anorexia⁸¹

Musculoskeletal and Connective Tissue Disorders: arthralgia⁷⁷, back pain⁹⁸, muscle cramps⁷⁸, muscle weakness⁷⁹, myalgia⁸⁰

Nervous System Disorders: hypoesthesia⁷¹, paresthesia⁷², tremor³⁰

Psychiatric Disorders: agitation²⁹, anxiety⁸², depression⁸³, insomnia⁸⁴, nervousness⁸⁵

Renal and Urinary Disorders: dysuria⁹¹, hematuria⁵⁸, micturition disorder⁹², micturition frequency⁹³, nocturia⁹⁴, polyuria¹⁰⁰, urinary incontinence⁵³

Reproductive System and Breast Disorder: gynecomastia⁷³, impotence³¹, priapism³⁸, retrograde ejaculation¹⁰⁵

Respiratory, Thoracic and Mediastinal Disorders: bronchospasm aggravated⁸⁶, coughing⁸⁷, dyspnea⁸⁸, epistaxis³⁶

Skin and Subcutaneous Tissue Disorders: alopecia⁸⁹, pruritus³³, purpura³⁴, skin rash³², urticaria⁹⁹

Vascular Disorders: hot flushes⁶⁶, hypotension⁶⁹, hypotension postural⁷⁰

The following additional adverse events have been reported in marketing experience among patients treated for hypertension but these, in general, are not distinguishable from symptoms that might have occurred in the absence of exposure to CARDURA[®] (doxazosin): bradycardia⁹⁵, tachycardia, palpitation, chest pain, angina pectoris, myocardial infarction, cerebrovascular accidents, and cardiac arrhythmias⁵³.

4.9 OVERDOSE

Should overdosage lead to hypotension, the patient should be immediately placed in a supine, head-down position. Other supportive measures should be performed if thought appropriate in individual cases. Since CARDURA[®] (doxazosin) is highly protein bound, dialysis is not indicated.

5. PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Hypertension

Administration of CARDURA[®] (doxazosin) to hypertensive patients causes a clinically significant reduction in blood pressure⁸ as a result of a reduction in systemic vascular resistance.⁹ This effect is thought to result from selective blockade of the alpha-1-adrenoceptors located in the vasculature.⁴ With once-daily dosing, clinically significant reductions in blood pressure are present throughout the day and at 24 hours post dose.¹⁰ A gradual reduction in blood pressure occurs,¹¹ with maximum reductions usually occurring 2 to 6 hours after dosing.¹² In patients with hypertension, blood pressures during treatment with doxazosin were similar in both the supine and standing positions.⁸ Unlike non-selective alpha-adrenoceptor blocking agents, tolerance has not been observed in long-term therapy with doxazosin. Elevations of plasma renin activity¹³ and tachycardia¹⁴ were seen infrequently in sustained therapy.

Doxazosin produces favorable effects on blood lipids, with a significant increase in the high-density lipoprotein (HDL)/total cholesterol ratio¹⁵ and significant reductions in total triglycerides and total cholesterol.^{16,17} It therefore confers an advantage over diuretics and beta-adrenoceptor blocking agents, which adversely affect these parameters.¹⁵ Based on the established association of hypertension and blood lipids with coronary heart disease, the favorable effects of CARDURA[®] (doxazosin) therapy on both blood pressure and lipids indicate a reduction in the risk of developing coronary heart disease.¹⁸

Treatment with CARDURA[®] (doxazosin) has been shown to result in regression of left ventricular hypertrophy, inhibition of platelet aggregation, and enhanced tissue plasminogen activator capacity.^{47,48,49,50,51} Additionally, CARDURA[®] (doxazosin) improves insulin sensitivity in patients who have impairment.⁵²

CARDURA[®] (doxazosin) has been shown to be free of adverse metabolic effects and is suitable for use in patients with asthma,¹⁹ diabetes,²⁰ left ventricular dysfunction, and gout.²¹

An *in vitro* study has demonstrated the antioxidant properties of the 6'- and 7'-hydroxy metabolites of doxazosin at concentrations of 5 micromolar.⁴⁶

In a controlled clinical trial in hypertensive patients, treatment with CARDURA[®] (doxazosin) was associated with improvement of erectile dysfunction. In addition, the patients who received CARDURA[®] (doxazosin) reported fewer new cases of erectile dysfunction than those who received other antihypertensive agents.³⁹

Benign Prostatic Hyperplasia

Administration of CARDURA[®] (doxazosin) to patients with symptomatic BPH results in a significant improvement in urodynamics and symptoms. The effect in BPH is thought to result from selective blockade of the alpha-adrenoceptors located in the muscular stroma and capsule of the prostate and in the bladder neck.^{40,41}

CARDURA[®] (doxazosin) has been shown to be an effective blocker of the 1A subtype of the alpha-1-adrenoceptor, which accounts for over 70% of the subtypes in the prostate. This accounts for the action in BPH patients.⁴²

CARDURA[®] (doxazosin) has demonstrated sustained efficacy and safety in the long-term treatment of BPH (i.e., up to 48 months).^{43,44,45}

5.2 PHARMACOKINETIC PROPERTIES

Absorption

After oral administration of therapeutic doses, doxazosin is well absorbed with peak blood levels occurring at about 2 hours.⁵

Biotransformation/Elimination

The plasma elimination is biphasic, with the terminal elimination half-life being 22 hours. This provides the basis for once-daily dosing.⁶ CARDURA[®] (doxazosin) is extensively metabolized, with <5% excreted as unchanged drug.⁵

Pharmacokinetic studies in patients with renal impairment have shown no significant alterations compared to patients with normal renal function.⁶¹

There are only limited data in patients with liver impairment and on the effects of drugs known to influence hepatic metabolism (e.g., cimetidine). In a clinical study in 12 subjects with moderate hepatic impairment, single-dose administration of CARDURA[®] (doxazosin) resulted in an increase in AUC of 43% and a decrease in apparent oral clearance of 40%.³ As with any drug wholly metabolized by the liver, use of doxazosin in patients with altered liver function should be undertaken with caution³ (see section 4.4 **Special warnings and precautions for use**).

Approximately 98% of doxazosin is protein-bound in plasma.^{62,23}

CARDURA[®] (doxazosin) is primarily metabolized by O-demethylation and hydroxylation.⁶³ Doxazosin is extensively metabolized in the liver. *In vitro* studies suggest that the primary pathway for elimination is via CYP 3A4; however, CYP 2D6 and CYP 2C9 metabolic pathways are also involved for elimination, but to a lesser extent.¹⁰⁹

5.3 PRECLINICAL SAFETY DATA

*Carcinogenesis*¹⁰¹

Chronic dietary administration (up to 24 months) of CARDURA[®] (doxazosin) at maximally tolerated doses of 40 mg/kg/day in rats and 120 mg/kg/day in mice revealed no evidence of carcinogenic potential. The highest doses evaluated in the rat and mouse studies are associated with AUCs (a measure of systemic exposure) that are 8 times and 4 times, respectively, the human AUC at a dose of 16 mg/day.

*Mutagenesis*¹⁰²

Mutagenicity studies revealed no drug- or metabolite-related effects at either chromosomal or subchromosomal levels.

*Impairment of Fertility*¹⁰³

Studies in rats showed reduced fertility in males treated with CARDURA[®] (doxazosin) at oral doses of 20 mg/kg/day (but not 5 or 10 mg/kg/day), about 4 times the human AUC at a dose of 12 mg/day. This

effect was reversible within 2 weeks of drug withdrawal. There have been no reports of any effects of CARDURA[®] (doxazosin) on male fertility in humans.

Lactation

Studies in lactating rats given a single oral dose of 1 mg/kg of [2-¹⁴C]-doxazosin indicate that doxazosin accumulates in rat breast milk with a maximum of concentration about 20 times greater than the maternal plasma concentration.¹¹⁰

6. PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

Doxazosin mesylate tablets include the following inert ingredients: sodium starch glycolate, microcrystalline cellulose, lactose, magnesium stearate and sodium lauryl sulfate.

6.2 INCOMPATIBILITIES

None

6.3 SHELF LIFE

3 years

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store below 30°C.

Avoid exposure to heat and sunlight and moisture

6.5 NATURE AND CONTENTS OF CONTAINER

CARDURA[®] (doxazosin) is available with the following presentations

- 2 mg tablets : 2x10's blister pack
- 4 mg tablets : 2x10's blister pack

6.6 INSTRUCTIONS FOR USE/HANDLING

Avoid exposure to heat and sunlight.

7. REFERENCES

1. Kaplan SA *et al.* Doxazosin in Physiologically and pharmacologically normotensive men with benign prostate hyperplasia: a study of safety and efficacy. *Urology* 1995; 46; 512-517.
2. Kirby RS, Doxazosin: safety relative to other medical therapies for benign prostate hyperplasia *European Journal of Urology* 1996; 29 (suppl. 1): 24-30.
3. Pfizer Final Study Report: Comparative Single Dose Pharmacokinetics of Doxazosin in Healthy and Hepatically Impaired Volunteers. Study Nos. 93-S-0504, 93-S-0057, August 1, 1995.
4. Singleton W., Saxton CAPD, Hernandez J. *et al.* Postjunctional selectivity of alpha- Blockade with Prazosin, Trimazosin, and UK-33,274 in Man. *J. Cardiovascl Pharmacol.* 1982; 4: S 145-S151.
5. Doxazosin NDA # 19, 668 Vol 2.1 F. p. 124-45, Table F2.
6. Doxazosin Mesylate tablets. Package to support change in the June IPD to half-life of 22. hours.
7. Doxazosin NDA 19,668. Vol. 5.5 Protocol 216. p. 1837-46.
8. Hayduk K. Efficacy and Safety of doxazosin in hypertension therapy. *Am J Cardiol* 1987; 59: 35G-39G.
9. Lund-Johansen P., Omvic P., Haughland H. Acute and chronic haemodynamic effects of doxazosin. *Br J Clin Pharmac.* 1986;21:45S-54S.
10. Doxazosin NDA #19-668. Vol. 7.65. Integrated summary of effectiveness. P. 25556.
11. Doxazosin NDA # 19-668 . Vol. 7.65. Integrated summary of effectiveness p.25571 Figures G .3.2- G 3.g.
12. Vincent J., Elliot HL, Meredith PA. Doxazosin, An alpha 1- adrenoceptor antagonist: Pharmacokinetics and Concentration – Effect Relationship in Man. *British Journal of Pharmac.* 1983;15:719-25.
13. Doxazosin NDA # 19, 668. Vol 7.8 Protocol 108 p. 2788.
14. Rosenthal J. A. Multicenter trial of Doxazosin in West Germany. *Am J Cardiol.* 1987;59:40G-45G.
15. Pool J. L. Plasma Lipid lowering effects of doxazosin, a new selective Alpha 1 adrenergic inhibitor for systemic hypertension. *Am J Cardiol.* 1987;59:46G-50G.
16. Doxazosin NDA #19-668. Summary Volume, p.259.
17. Doxazosin NDA #19-668. Vol. 7.14-15 Study # 106 p. 5293.
18. Wilson PWF, Castelli WP, Kennel WB. Coronary risk prediction in adults (the Framingham heart study) . *Am J Cardiol.* 1987;59:91G-4G.
19. Doxazosin NDA #19-668. Vol. 7.65. Integrated Summary of safety p. 25638.

20. Doxazosin NDA #19-668 Vol. 7.65. Integrated Summary of safety p. 25638.
21. Doxazosin NDA #19-668 Vol. 7.65. Integrated Summary of safety. p.25642.
22. Doxazosin NDA #19-668. Vol. 2.1 Section E.2. p.98.
23. Doxazosin NDA #19-668 Vol. 2.1. Non clinical pharmacology and toxicology p.112.
24. Doxazosin NDA #19-668 Vol. 5.7 Section 5f. Human Bioavailability and pharmacokinetics (Appendix). p.3109-13.
25. Doxazosin NDA #19-668 Vol. 7.65 Integrated Summary of safety p. 25644.
26. Doxazosin NDA #19-668 Vol. 7.65 Integrated summary of safety. p. 25603.
27. Doxazosin IRD. June 1968. Vol. 6. Subject characteristics and dosage p.20-3.
28. Doxazosin and Abdominal Events, Pfizer Safety Database Report, March 24, 1997
29. Doxazosin and Agitation, Pfizer Safety Database Report, March 24, 1997
30. Doxazosin and Tremor, Pfizer Safety Database Report, March 24, 1997
31. Doxazosin and Impotence, Pfizer Safety Database Report, March 24, 1997
32. Doxazosin and Rash, Pfizer Safety Database Report, March 24, 1997
33. Doxazosin and Pruritus, Pfizer Safety Database Report, March 24, 1997
34. Doxazosin and Purpura, Pfizer Safety Database Report, March 24, 1997
35. Doxazosin and Liver/Biliary Events, Pfizer Safety Database Report, March 24, 1997
36. Doxazosin and Epistaxis, Pfizer Safety Database Report, March 24, 1998
37. Doxazosin and Blurred Vision, Pfizer Safety Database Report, March 24, 1997
38. Alpha 1 – Blockers and Priapism, Pfizer Safety Database Report, July 25, 1996.
39. Grimm R.H. *et al.* Incidence and disappearance of erectile problems in men treated for stage 1 hypertension: the treatment of mild hypertension study (TOHMS). *Journal of Urology* 1996; 155 (5) 469A (# 634).
40. Hatano A. *et al.* The Alpha-adrenoreceptor antagonist properties of the enantiomers of doxazosin in the human prostate, adenoma and cloned human alpha-1-subtypes. *Journal of Urology* 1996; 155 (5): 534A (#895).
41. Lepor H. *et al.* Binding and functional properties of doxazosin in the human prostate adenoma and canine brain. *The Prostate* 1990; 16:29-38.

42. Kenny B. *et al.* Alpha-1-adrenoceptor antagonists as treatments for benign prostatic hyperplasia. *Exp. Opin. Invest. Drugs* 1995; 4 (10): 915-923.
43. Fawzy A *et al.*, Long-term (4 year) efficacy of doxazosin for the treatment of benign prostatic hyperplasia. *Journal of Urology* 1996; 155 (5) 573A (#1051).
44. Lepor H. Long-term efficacy and safety of doxazosin for the treatment of benign prostatic hyperplasia. *Journal of Urology* 1995; 153: 273A (#180).
45. Lepor H. *et al.* Doxazosin in benign prostatic hyperplasia: long term efficacy and safety in hypertensive and normotensive patients. *Journal of Urology*. 1997; 157: 525-530.
46. Chait A *et al.* Inhibition of low-density lipoprotein oxidation *in vitro* by the 6- and 7-hydroxy-metabolites of doxazosin, an alpha-1-adrenergic antihypertensive agent. *American Journal of Hypertension* 1994; (2): 159-167.
47. Hernandez R. *et al.* Evidence of antiplatelet aggregation action of doxazosin in patients with hypertension: An *ex vivo* study. *American Heart Journal* 1991; 121(1): 395-401.
48. Hernandez R. *et al.* The effect of doxazosin on platelet aggregation in normotensive subjects and patients with hypertension: An *in vitro* study. *American Heart Journal* 1991; 121(1): 389-394.
49. Monsalve P. *et al.* Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension. *American Heart Journal* 1991 121 (1): 356-361.
50. Corral J. *et al.* Doxazosin in the treatment of mild or moderate essential hypertension: An echocardiographic study. *Am Heart Journal* 1991; 121(1): 352-356.
51. Jansson J. *et al.* Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol. *European Journal of Clinical Pharmacology* 1991; 40: 321-326
52. Huupponen, R. *et al.* Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients. *European Journal of Clinical Pharmacology* 1992; 43: 365-368.
53. NDA #19-668 and data on file
54. Miura Y. *et al.* An evaluation of the efficacy and safety of doxazosin in hypertension associated with renal dysfunction. *American Heart Journal* 1991; 121(1): 381-388.
55. Anderton J. *et al.* An evaluation of the efficacy and safety of doxazosin in the treatment of hypertension associated with renal insufficiency. *Journal of Human Hypertension* 1990; 4(3) 52-57.
56. Bartels A. *et al.* Doxazosin in the treatment of patients with mild or moderate hypertension and mild or moderate renal insufficiency. *American Heart Journal* 1988; 6 (2) 1772-1777.
57. NDA for BPH and IRD
58. Doxazosin and Hematological Events, Pfizer Safety Database Report, July 10, 1998
59. Doxazosin and Hepatic Events, Pfizer Safety Database Report, June 23, 1998

60. Doxazosin NDA #19-668 Vol. 2.1 Summary Section E.3. p.110 & Vol. 4.8 Section 4.g p.3027.
61. Carlson RV *et al.* Pharmacokinetics and effect on blood pressure of doxazosin in normal subjects and patients with renal failure. Clin Pharmacol Ther 1986, 40: 561-566.
62. Doxazosin NDA #19-668 Vol. 5.1 Section A, p. 1B.
63. Doxazosin NDA #19-668 Vol. 5.1 Section A, p. 2.
64. Worldwide Labeling Safety Report: Mouth Dry and Doxazosin 30Jun99
65. Worldwide Labeling Safety Report: Allergic Reaction and Doxazosin 30Jun99
66. Worldwide Labeling Safety Report: Hot Flushes and Doxazosin 30Jun99
67. Worldwide Labeling Safety Report: Pain and Doxazosin 30Jun99
68. Worldwide Labeling Safety Report: Weight Increase and Doxazosin 30Jun99
69. Worldwide Labeling Safety Report: Hypotension and Doxazosin 30Jun99
70. Worldwide Labeling Safety Report: Hypotension Postural and Doxazosin 30Jun99
71. Worldwide Labeling Safety Report: Hypoesthesia and Doxazosin 30Jun99
72. Worldwide Labeling Safety Report: Paresthesia and Doxazosin 30Jun99
73. Worldwide Labeling Safety Report: Gynecomastia and Doxazosin 30Jun99
74. Worldwide Labeling Safety Report: Constipation and Doxazosin 30Jun99
75. Worldwide Labeling Safety Report: Dyspepsia and Doxazosin 30Jun99
76. Worldwide Labeling Safety Report: Flatulence and Doxazosin 30Jun99
77. Worldwide Labeling Safety Report: Arthralgia and Doxazosin 30Jun99
78. Worldwide Labeling Safety Report: Muscle Cramps and Doxazosin 30Jun99
79. Worldwide Labeling Safety Report: Muscle Weakness and Doxazosin 30Jun99
80. Worldwide Labeling Safety Report: Myalgia and Doxazosin 30Jun99
81. Worldwide Labeling Safety Report: Anorexia and Doxazosin 30Jun99
82. Worldwide Labeling Safety Report: Anxiety and Doxazosin 30Jun99
83. Worldwide Labeling Safety Report: Depression and Doxazosin 30Jun99
84. Worldwide Labeling Safety Report: Insomnia and Doxazosin 30Jun99

85. Worldwide Labeling Safety Report: Nervousness and Doxazosin 30Jun99
86. Worldwide Labeling Safety Report: Bronchospasm Aggravated and Doxazosin 30Jun99
87. Worldwide Labeling Safety Report: Coughing and Doxazosin 30Jun99
88. Worldwide Labeling Safety Report: Dyspnea and Doxazosin 30Jun99
89. Worldwide Labeling Safety Report: Alopecia and Doxazosin 30Jun99
90. Worldwide Labeling Safety Report: Tinnitus and Doxazosin 30Jun99
91. Worldwide Labeling Safety Report: Dysuria and Doxazosin 30Jun99
92. Worldwide Labeling Safety Report: Micturition Disorder and Doxazosin 30Jun99
93. Worldwide Labeling Safety Report: Micturition Frequency and Doxazosin 30Jun99
94. Worldwide Labeling Safety Report: Nocturia and Doxazosin 30Jun99
95. Worldwide Labeling Safety Report: Bradycardia and Doxazosin 30Jun99
96. Rhode S, Zhang T, Aggarwal R. Doxazosin and Doxazosin GITS: Syncope, Postural Hypotension, Accidental Fall, and Accidental Injury. 15November2000
97. Final Study Report: Protocol 035-011. Phase I Study to Assess the Potential of Cimetidine to Alter the Disposition of Doxazosin in Healthy Volunteers 02October1991
98. Worldwide Labeling Safety Report: Back Pain and Doxazosin 08May2001
99. Worldwide Labeling Safety Report: Urticaria and Doxazosin 08May2001
100. Worldwide Labeling Safety Report: Polyuria and Doxazosin 08May2001
101. Doxazosin NDA #19-668 Vol. 4.4-4.5 "Two Year Toxicity Study in Rats" (Protocol #81042 and #81074) p.1553.
102. Doxazosin NDA #19-668 Vol. 4.7 "Genetic Toxicology Report and Addendum: Mammalian Cell Point Mutation Assays" p.2668.
103. Doxazosin NDA #19-668 Vol. 4.7 "Male Fertility Study In Rats by the Oral Route" (Protocol # 80097) p.2738.
104. Bell, D. Co-administration of Doxazosin with PDE-5 Inhibitor Clinical Expert Report. Pfizer Inc, July 15, 2004
105. Nicoletta, S. DOXAZOSIN AND RETROGRADE EJACULATION AND RELATED EVENTS. Safety Analysis Report Pfizer, Inc. March 14, 2006.
106. USPI March, 2008

107. Clinical Overview, Evaluation of Cases Reported with Doxazosin and Prazosin Potentially Related to Intraoperative Floppy Iris Syndrome (IFIS), 24 July 2008, Pfizer, Inc.

108. Sep 2014 Doxazosin mesylate 2.5 Clinical Overview for CDS Update_Addition of Priapism in section 4.4.

109. April 2016_Doxazosin_2 5 Clinical Overview for CDS Updates_Addition of CYP3A4 inhibitors.

110. July 2016 Doxazosin mesylate 2.5 Clinical overview for use of Doxazosin During Pregnancy and Lactation and the Drug's Potential Effects on Fertility.

Document Approval Record

Document Name: LPD doxazosin mesilate - Cardura

Document Title: LPD doxazosin mesilate - Cardura

Signed By:	Date(GMT)	Signing Capacity
Patel, Bushra Muzamil	06-Jan-2017 08:17:25	Regulatory Affairs Approval